Nls pharmaceutics announces preclinical data demonstrating the potential of nls-4 (lauflumide) to treat chronic fatigue associated with long-covid

Stans, switzerland / accesswire / october 14, 2021 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces preclinical data for nls-4 (lauflumide), the company's next-generation wake-promoting drug candidate, which has shown promise for the treatment of chronic fatigue associated with long-covid (also known as "chronic covid syndrome").
NLSP Ratings Summary
NLSP Quant Ranking